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An analysis of temporal and generational trends in the incidence of
anal and other HPV-related cancers in Southeast England
D Robinson*,1, V Coupland1 and H Møller1
1Thames Cancer Registry, Division of Cancer Studies, King’s College London, 1st Floor, Capital House, Weston Street, London SE1 3QD, UK
Patients diagnosed in 1960–2004 with cancer of the cervix, anus, vulva, vagina or penis were identified from the Thames Cancer
Registry database, and age-standardised period (temporal) incidence rates calculated by direct standardisation. Age-cohort modelling
techniques were used to estimate age-specific incidence rates in the earlier and later cohorts, enabling the calculation of age-
standardised cohort (generational) rates. Incidence of anal cancer increased for both men and women over the period studied, mainly
in those born from 1940 onwards. Similar generational patterns were seen for cancers of the vulva and vagina, but those for penile
cancer were different. For cervix cancer, the steep downward trend in cohort rates due to screening levelled off in women born from
1940 onwards. Our findings are compatible with the hypothesis that changes in sexual practices were a major contributor to the
increases of these cancers. Programmes of vaccination against HPV, aimed at reducing the burden of cervical cancer, may also help to
reduce the incidence of cancer at other anogenital sites.
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Human papillomavirus (HPV), a sexually transmitted pathogen
infecting the anogenital epithelium, is the major cause of cervix
cancer. In cervical cancer, HPV infection is the major cause
(Schiffman et al, 1993; International Agency for Research on
Cancer, 1995; zur Hausen, 1996; Walboomers et al, 1999; Schlecht
et al, 2001; Bosch et al, 2002; Schiffman et al, 2007; Bosch and de
Sanjose´, 2003), and positive associations have been found between
HPV infection and cancers of the anus (Daling and Sherman, 1992;
Frisch et al, 1997; Daling et al, 2004; Bjørge et al, 2002), vulva and
vagina (Madeleine et al, 1997; Daling et al, 2002; Goffin et al, 2006;
Madsen et al, 2008). Cancers of the anus, vulva and vagina occur
more frequently than expected following cervical intraepithelial
neoplasia III or invasive cervical cancer, suggesting a strong
common aetiological factor (Evans et al, 2003). HPV infection may
also play a role in a subset of penile squamous cell carcinomas
(Iwasawa et al, 1993; Rubin et al, 2001; Daling et al, 2005;
Heideman et al, 2007; Tornesello et al, 2008).
Increasing trends in anal cancer have been reported, possibly
due to changes in sexual practices (Daling et al, 1987; Scholefield
et al, 1990; Frisch et al, 1993, 1997). If this were the case, a strong
generational effect would be expected in the incidence trends of
anogenital cancers. We have explored this hypothesis by plotting
age-standardised period (temporal) and cohort (generational)
rates for cancer sites linked to HPV infection.
METHODS
Patients diagnosed in 1960–2004 with cancer of the anus (ICD-10
code C21), vulva (C51), vagina (C52), cervix uteri (C53) or penis
(C60) were identified from the Thames Cancer Registry (TCR)
database. TCR is a population-based registry, which in this period
covered a population of approximately 12 million residents of
London and southeast England. All tumours are coded according
to the ICD-O classification (World Health Organization, 1976), and
were retrospectively recoded to the ICD-10 classification in the
case of tumours diagnosed before its introduction in the early
1990s. Examination of proportional frequency plots revealed no
coding discrepancies or inconsistencies over the period of the
study. Age at diagnosis was categorised into 5-year groups (0– 4,
5–9,y, 80–84, 85þ ), and period of diagnosis into 5-year periods
(1960–1964, 1965–1969, y, 2000– 2004). Nominal birth cohort
groups (1875, 1880, y, 2000) were then calculated by subtracting
the midpoint of the age group from the midpoint of the period. For
each site, an age-standardised incidence rate for each calendar
period was calculated by direct standardisation, using the
European standard population. As the earlier and later birth
cohorts were missing data from the younger and older age groups,
respectively, a Poisson regression age-cohort modelling technique
(Clayton and Schifflers, 1987) was used to estimate the unavailable
rates, enabling the estimation of an age-standardised incidence
rate for each cohort. As estimates for later cohorts (represented by
younger patients diagnosed in recent periods) were based on small
numbers of cases, and hence relatively unreliable, we report only
estimates for birth cohorts between 1885 and 1960.
RESULTS
Table 1 shows the total number of cancers diagnosed over the
study period and the incidence by age for each site. Incidence
increases with age at all sites, with few cases (other than cervical
cancer cases) occurring before age 55.
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Figure 1A shows a modest increase in age-standardised period
rates for anal cancer in both men and women. In men, these
increased from 0.79 in 1960–64 to 1.06 per 100 000 in 2000–2004.
In women, the increase was greater, from 0.45 in 1960–64 to 1.18
per 100 000 in 2000–2004. In both sexes, rates for consecutive
cohorts (Figure 1B) remained relatively constant (between 0.5 and
1.1 per 100 000) for individuals born between 1885 and 1935. There
was then a sharp increase in rates in the subsequent generations
born from 1940 onwards. In men, the rates increased from 0.92 in
the 1935 cohort to 1.71 per 100 000 in the 1960 cohort, whereas in
women the increase was from 0.97 in the 1935 cohort to 4.18 per
100 000 in the 1960 cohort.
Figure 2A and B show age-standardised rates, by period and
cohort, respectively, for cancers of the vulva and vagina. Period
rates have remained fairly constant since the early 1990s, whereas
cohort rates have increased in recent generations: for vaginal
cancer, from 0.42 in the 1940 cohort to 0.82 per 100 000 in the 1960
cohort; the corresponding rise for vulval cancer was from 1.65 to
2.51. For penile cancer, period rates have remained fairly constant,
whereas cohort rates have been erratic, with no clear pattern
emerging (Figure 3A and B).
Figure 4A and B show age-standardised period and cohort rates
for cervical cancer. Period rates have shown a dramatic decline from
12.68 in those diagnosed between 1985 and 1990 to 6.66 per 100 000
in 2000–04. Cohort rates declined from 21.27 in the 1885 cohort to
7.64 per 100 000 in the 1935 cohort, after which they remained
relatively constant. Table 2 summarises these results, showing the
age-standardised rates and associated 95% confidence levels.
DISCUSSION
Anal cancer incidence in southeast England increased in both men
and women over the study period (1960–2004), by threefold in
women and about 1.5-fold in men; the incidence is now higher in
women than in men. Similar trends have been seen in Denmark
(Frisch et al, 1993), the United States of America (Melbye et al,
1994; Johnson et al, 2004) and Sweden (Goldman et al, 1989).
Increases have also been reported in Scotland (Brewster and
Bhatti, 2006), where the change in male rates has roughly
paralleled that in the female rates from the mid-1970s to the
mid-1990s. Male rates have since plateaued, whereas female rates
have continued to rise. In Scotland the female rates were higher
than the males rates throughout the period studied, whereas in our
population these were initially lower than in men, but became
higher from the early 1990s onwards.
Judson et al (2006) found a 20% increase in invasive vulval
cancer in the United States of America between 1973 and 2000. No
increase was seen in the period rates for vulval cancer in our data,
nor any increase in the period rates for cancers of the vagina or
penis.
The dramatic decline in rates for cervical cancer from the late
1980s onward is similar to that reported in the West Midlands
(Clare et al, 2008), and reflects the introduction of the National
Health Service’s screening programme around 1988, which has led
to the early detection of precancerous cervical lesions and the
prevention of many invasive cancers.
In our study, in both sexes a marked increase was found in the
cohort rates for anal cancer in those born from around 1940
onwards. Similar generational patterns were seen for cancers of the
vulva and vagina, consistent with a common aetiology. The most
likely causes are changes in sexual practice and greater exposure to
infectious agents such as HPV. For cancer of the cervix, for which
HPV is generally recognised as the major cause, the steep
downward trend in cohort rates due to screening levelled off in
women born from 1940 onwards.
We found no clear-cut change in cohort rates for penile cancer,
although on average the rates for generations born after 1940 were
Table 1 Cancer incidence rates per 100 000 by age at diagnosis
Age
Cancer site o35 35–44 45–54 55–64 65–74 75–84 85+ Total cancers diagnosed
Anus, males 0.02 0.39 0.97 2.14 3.41 5.45 7.28 1988
Anus, females 0.03 0.44 1.18 1.95 3.37 4.75 6.60 2676
Vulva 0.09 0.74 1.46 3.15 7.44 14.24 22.86 6216
Vagina 0.04 0.24 0.66 1.06 1.80 3.46 4.19 1639
Penis 0.04 0.46 0.94 1.92 3.49 6.08 10.24 2082
Cervix 2.93 16.21 18.34 19.89 20.25 20.34 19.43 25854
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Figure 1 Anal cancer. (A) Age-standardised rates by period. (B) Age-standardised rates by cohort.
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higher than in previous cohorts. It may be that the effect of HPV
infection is less in penis cancer than in the other cancers, as
recently suggested (Tornesello et al, 2008).
Several studies have linked sexual behaviour with cancer of the
anus (Daling et al, 1987; Scholefield et al, 1990; Frisch et al, 1993,
1997). In both Denmark (Melbye and Biggar, 1992) and Scotland
(Brewster and Bhatti, 2006) a higher prevalence of receptive anal
intercourse in women than in men has been reported, and may
explain in part the higher incidence of anal cancer in women in
these countries. Sexual practices have also been implicated in
cancers of the vagina and vulva (Sherman et al, 1991; Madsen et al,
2008) and of the penis (Maden et al, 1993).
It should be noted that the cohorts which show the recent
increases in incidence are, of necessity, based partially on
modelled data, because observational data in the older age groups
are not available. However, the variability introduced by the
modelling procedure has been included in the calculation of the
standard errors of the estimated rates. As can be seen from Table 2,
none of the estimates exhibits excessive variation.
The generational patterns seen in the cohort rates presented in
this paper, with a marked change from around 1940, while not
constituting proof, are compatible with the hypothesis that
changes in sexual practices are a major contributor to the
increases in anogenital cancers other than the cervix. Those born
around 1940 would have been in their early twenties at the start of
the ‘sexual revolution’ in the early 1960s.
Peto et al (2004) have estimated that ‘cervical cancer screening
has prevented an epidemic that would have killed about one in 65
of all British women born since 1950 and culminated in 6000
deaths per year in this country’. Trials of vaccination against HPV
in teenage girls are currently underway in the United Kingdom. In
Australia, it has been predicted that the public vaccination
programme begun in 2007 will result in a reduction in the age-
standardised incidence of HPV-16 infections of 56% by 2010 and
92% by 2050 (Smith et al, 2008). Programmes of vaccination,
aimed at reducing the burden of cervical cancer, may also help to
reduce the incidence of cancers of the vulva, vagina and anus in
women.
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Figure 2 Vulval and vaginal cancers. (A) Age-standardised rates by period. (B) Age-standardised rates by cohort.
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Figure 3 Penile cancer. (A) Age-standardised rates by period. (B) Age-standardised rates by cohort.
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